Frank Beurskens

This inventor holds 16 USPTO granted patents and 28 published patent applications and 5 EPO patents, primarily in Antibody Variants. Top assignees: Genmab B.v., Genmab Holding B.v., Genmab A+s. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Frank Beurskens. Retrieved from https://idiyas.com/inventor/frank-beurskens

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 28)

% Patents Active = 81.3

EPO Patents = 5 (Patent Applications = 16)

Average Co-Inventor Count = 7.4

ph-index = 5

Forward Citations = 45(Granted Patents)

Location History:

Culemborg, NL (2016 - 2020)
Utrecht, NL (2018 - 2024)

Company Filing History:

Morgan Stanley Senior Funding, Inc.

patents

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

Antibody Variants

Bispecific Antibodies

Monoclonal Antibodies

Polypeptide Variants

Recombinant Antibodies

Dimeric Proteins

Triple Mutations

IgG4 Antibodies

Compositions

Methods of Use

Combination Therapies

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12780930 - ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF (2026-11-03),

2. 12668641 - ANTIBODY VARIANT COMBINATIONS AND USES THEREOF (2026-06-30),

3. 12649798 - POLYPEPTIDE VARIANTS AND USES THEREOF (2026-06-09),

4. 12448459 - Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof (2025-10-21),

5. 12338289 - Antibody variant combinations and uses thereof (2025-06-24),

6. 12275797 - Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof (2025-04-14),

7. 12173076 - Polypeptide variants and uses thereof (2024-12-24),

8. 12049512 - Antibody variants and uses thereof (2024-07-30),

9. 11512137 - Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof (2022-11-29),

10. 11396553 - Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof (2022-07-26),

11. 11180572 - Dimeric protein with triple mutations (2021-11-23),

12. 11034772 - Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof (2021-06-15),

13. 10759867 - Antibody variants and uses thereof (2020-09-01),

14. 10351629 - Recombinant IgG4 monovalent antibodies (2019-07-16),

15. 10155816 - Recombinant monovalent antibodies and methods for production thereof (2018-12-18),

Title: The Innovative Journey of Frank Beurskens: Pioneering Cancer Treatments.

Introduction:

Frank Beurskens, a visionary inventor hailing from Utrecht, Netherlands, has made significant strides in the field of biotechnology with a total of 8 patents to his name. His groundbreaking work in developing bispecific anti-CD37 antibodies has revolutionized cancer treatment methodologies.

Latest Patents:

Frank Beurskens' most recent patents center around the creation of CD37-specific bispecific antibody molecules that bind to different epitopes of the human CD37 antigen, exhibiting enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. These inventions also encompass the pharmaceutical compositions containing these molecules, offering novel approaches to the treatment of various diseases, especially cancer.

Career Highlights:

Having contributed his expertise to renowned companies such as Genmab Holding B.V. and Genmab A/S, Frank Beurskens has honed his craft in the biopharmaceutical industry. His relentless pursuit of innovative solutions has led to the development of cutting-edge therapies that hold promise for patients worldwide.

Collaborations:

Throughout his illustrious career, Frank Beurskens has collaborated with esteemed professionals in the field, including notable coworkers such as Paul Parren and Janine Schuurman. Together, they have worked tirelessly to push the boundaries of scientific innovation and improve medical treatment options for those in need.

Conclusion:

In conclusion, Frank Beurskens stands as a beacon of innovation, consistently pushing the envelope in the realm of biotechnology. His dedication to advancing cancer therapies through novel antibody molecules underscores his commitment to making a positive impact on the world. As he continues to drive forward progress in the field, the legacy of his inventive spirit is sure to endure for years to come.

Profile summary based on public USPTO records.